Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Labiofam is a prominent Cuban state-owned biotechnology and pharmaceutical conglomerate specializing in the development and production of vaccines, medicines, and biological products for both human and veterinary use. The company is internationally recognized for its research into natural products, most notably Vidatox, a homeopathic cancer treatment derived from the venom of the blue scorpion (Rhopalurus junceus). Beyond human health, Labiofam is a global leader in vector control and agricultural biotechnology, producing bio-pesticides and bio-fertilizers used to combat diseases like malaria and dengue. The organization operates multiple manufacturing plants across Cuba and has established production facilities in several countries in Africa and Asia to support regional health initiatives. Labiofam's business model emphasizes South-South cooperation, exporting its diverse portfolio of over 200 products to more than 60 countries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Labiofam.